Clinical trial: a novel high-dose 1 g mesalamine suppository (Salofalk) once daily is as efficacious as a 500-mg suppository thrice daily in active ulcerative proctitis.
Andus, Tilo
Clinical trial: a novel high-dose 1 g mesalamine suppository (Salofalk) once daily is as efficacious as a 500-mg suppository thrice daily in active ulcerative proctitis. [electronic resource] - Inflammatory bowel diseases Nov 2010 - 1947-56 p. digital
Publication Type: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
1536-4844
10.1002/ibd.21258 doi
Adolescent
Adult
Aged
Anti-Inflammatory Agents, Non-Steroidal--administration & dosage
Colitis, Ulcerative--drug therapy
Drug Administration Schedule
Female
Humans
Male
Mesalamine--administration & dosage
Middle Aged
Patient Preference
Proctitis--drug therapy
Remission Induction
Single-Blind Method
Suppositories
Young Adult
Clinical trial: a novel high-dose 1 g mesalamine suppository (Salofalk) once daily is as efficacious as a 500-mg suppository thrice daily in active ulcerative proctitis. [electronic resource] - Inflammatory bowel diseases Nov 2010 - 1947-56 p. digital
Publication Type: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
1536-4844
10.1002/ibd.21258 doi
Adolescent
Adult
Aged
Anti-Inflammatory Agents, Non-Steroidal--administration & dosage
Colitis, Ulcerative--drug therapy
Drug Administration Schedule
Female
Humans
Male
Mesalamine--administration & dosage
Middle Aged
Patient Preference
Proctitis--drug therapy
Remission Induction
Single-Blind Method
Suppositories
Young Adult